Hemotune Secures CHF 14 Million for Clinical Trials

Tue, Mar 26th 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Hemotune Secures CHF 14 Million for Clinical Trials
Photo courtesy of Hemotune

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

Related Stories

Swisscom CEO Does Not Comment on Vodafone Rumors
Thumbnail

Swisscom explores Italian energy sector expansion amidst telecom revenue dip in Switzerland, sidelin...

Switzerland Will Not Summon the Russian Ambassador over Navalny Death
Thumbnail

Navalny's Death: Switzerland Advocates for Clarity, Balancing Neutrality with a Call for Justice...

Swiss Federal Intelligence Service Faces Internal Challenge
Thumbnail

Internal challenges at the Swiss Federal Intelligence Service, including leadership concerns and the...

One in Three Swiss Companies Admits to Bribery Abroad
Thumbnail

Over 50% of Swiss companies encounter corruption demands abroad, with many yielding to such pressure...

UBS Posts Fourth Quarter Loss of $279 Million
Thumbnail

UBS experiences a Q4 2023 loss but announces higher dividends and future share buybacks, amidst cost...

Fewer Mergers and Acquisitions Last Year
Thumbnail

Swiss M&A sees a decline to 484 deals in 2023, down from 2022's peak, with Glencore's moves making h...

Aktiia Secure CHF 27 Million in Funding to Fight Hypertension
Thumbnail

Aktiia secures CHF 27 million in financing to help hypertension management with its wearable technol...

Stay in Touch

Noteworthy

the swiss times
A production of UltraSwiss AG, 6340 Baar, Switzerland
Copyright © 2024 UltraSwiss AG 2024 All rights reserved